First patients to test new oral cancer drug targeting specific mutations
NCT ID NCT06983743
Summary
This is the first study in humans testing a new oral cancer drug called ERAS-0015. Researchers want to find the safest dose and see if it helps control advanced solid tumors that have spread and have specific genetic changes. The drug will be tested alone and combined with other treatments in about 200 patients who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Florida Cancer Specalists
RECRUITINGSarasota, Florida, 34232, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
University of Texas at Tyler
RECRUITINGTyler, Texas, 75701, United States
Conditions
Explore the condition pages connected to this study.